Fairley, Jennifer A.
Cheetham, Melanie H.
Patton, Simon J.
Rouleau, Etienne
Denis, Marc
Dequeker, Elisabeth M. C.
Schuuring, Ed
van Casteren, Kaat
Fenizia, Francesca
Normanno, Nicola
Deans, Zandra C.
Article History
Received: 16 March 2022
Accepted: 1 July 2022
First Online: 12 July 2022
Declarations
:
: Not applicable as the study did not involve human participants or human material.
: Not applicable.
: ZCD: Advisory Boards for AstraZeneca, lectures and webinars for AstraZeneca and Merck MSD.JAF Advisory Board for Eli Lilly, lectures for AstraZeneca.ES reports providing lectures for Bio-Rad, Novartis, Roche, Biocartis, Illumina, Pfizer, AstraZeneca, and Agena Bioscience, advisory board presence for AstraZeneca, Roche, Pfizer, Novartis, Bayer, Lilly, BMS, Amgen, Biocartis, Illumina, Agena Bioscience and MSD/Merck, and research grants from Pfizer, Biocartis, Invitae-ArcherDX, AstraZeneca, Agena Bioscience, BMS, Bio-Rad, Roche, Boehringer Ingelheim, all outside the submitted work and all financial supports transferred to Institute.MD Personal fees (advisory board and lectures) from AstraZeneca, Takeda, BMS, Boehringer Ingelheim, Pfizer, Roche Diagnostics, and Amgen. Grants from BluePrint Medicines and Takeda.NN Personal and/or Institutional financial interests: Thermofisher, QIAGEN, Roche, Astrazeneca, Biocartis, Illumina.ER Personal fees (consulting and travel) – AstraZeneca, BMS, Roche.SJP, MHC, KVC, FF and EMCD have no interests to declare.